Degradable intrauterine system for the prolonged release of an active ingredient in the uterine cavity

Patent metadata

Field	Value
Publication number	US-2025332093-A1
Application number	US-202218698796-A
Country	US
Kind code	A1
Filing date	Oct 4, 2022
Priority date	Oct 5, 2021
Publication date	Oct 30, 2025
Grant date	—

Abstract

The present invention relates to a degradable intrauterine system for the prolonged release of an active ingredient in the uterine cavity comprising (a) a degradable A and B block copolymer, wherein the A block is a polyester, the B block is a poly (oxyethylene) (PEO) with a weight-average molecular weight of greater than or equal to 50 kDa; and the ethylene oxide unit/ester unit molar ratio is between 0.05 and 5; (b) at least one polyester homopolymer; and (c) at least one active ingredient intended to be released in the uterine cavity. The invention also relates to a kit comprising at least one intrauterine system according to the invention and means for inserting the system into the uterine cavity.

First claim

1 - 15 . (canceled)

16 . A degradable intrauterine system for the prolonged release of an active ingredient in the uterine cavity comprising:
(a) a degradable A and B block copolymer, wherein: the A block is a polyester; the B block is a poly(oxyethylene) (PEO) with a weight-average molecular weight of greater than or equal to 50 kDa; and the ethylene oxide unit/ester unit molar ratio is between 0.05 and 5; (b) at least one polyester homopolymer; and (c) at least one active ingredient for release in the uterine cavity.

17 . The degradable intrauterine system according to claim 16 , wherein the copolymer (a)/homopolymer (b) weight ratio is between 99/1 and 1/99.

18 . The degradable intrauterine system according to claim 17 , wherein the copolymer (a)/homopolymer (b) weight ratio is between 95/5 and 5/95.

19 . The degradable intrauterine system according to claim 16 , wherein the A and B block copolymer is selected from AB diblock copolymers and ABA and BAB triblock copolymers, and mixtures thereof.

20 . The degradable intrauterine system according to claim 19 , wherein the A and B block copolymer is selected from ABA and BAB triblock copolymers, and mixtures thereof.

21 . The degradable intrauterine system according to claim 16 , wherein the weight-average molecular weight of the B blocks in the A and B block copolymer is between 75 kDa and 150 kDa.

22 . The degradable intrauterine system according to claim 21 , wherein the weight-average molecular weight of the B blocks in the A and B block copolymer is between 80 and 125 kDa.

23 . The degradable intrauterine system according to claim 16 , wherein the ethylene oxide unit/ester unit ratio of the A and B block copolymer is from 0.1 to 4.

24 . The degradable intrauterine system according to claim 23 , wherein the ethylene oxide unit/ester unit ratio of the A and B block copolymer is from 0.1 to 3.

25 . The degradable intrauterine system according to claim 16 , wherein the A block is selected from poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), polybutyrolactone (PBL), polyhydroxyalkanoates (PHA), and copolymers thereof.

26 . The degradable intrauterine system according to claim 16 , wherein the A block is a polycaprolactone (PCL) or a poly(lactic acid) (PLA) comprising at least 50% of L-lactic acid.

27 . The degradable intrauterine system according to claim 16 , wherein the homopolymer (b) is selected from poly(lactic acid) (PLA), poly glycolic acid) (PGA), poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), polybutyrolactone (PBL) and polyhydroxyalkanoates (PHA), and mixtures thereof.

28 . The degradable intrauterine system according to claim 27 , wherein the homopolymer (b) is a PLA and/or PCL.

29 . The degradable intrauterine system according to claim 16 , wherein the homopolymer (b) has a number-average molar mass of between 25,000 g/mol and 250,000 g/mol.

30 . The degradable intrauterine system according to claim 16 , wherein the active ingredient for release in the uterine cavity is selected from antibiotics, antifungals or antivirals; steroidal or non-steroidal anti-inflammatory drugs; vasoconstrictors; vasodilators;
uterine relaxants; oxytocics; hormones, hormone analogues, hormone agonists, hormone antagonists; anti-cancer drugs; or mixtures thereof.

31 . The degradable intrauterine system according claim 16 , wherein the content of active ingredient is between 0.01% and 60% by weight.

32 . The degradable intrauterine system according to claim 16 , wherein the active ingredient is not covalently bound to the copolymer a) or to the homopolymer b).

33 . The degradable intrauterine according to claim 16 , said system releasing the active ingredient over at least 10 days.

34 . The degradable intrauterine system according to claim 16 , said system degrading after a residence time in an aqueous or humid environment of between 10 days and 1 2months.

35 . A kit comprising at least one intrauterine system according to claim 16 and means for inserting the system into the uterine cavity.

Assignees

• Womed
• Centre Nat Rech Scient
• Univ Montpellier
• Enscm

Inventors

• Garric Xavier
• Issenmann Gonzague
• Leprince Salomé

Classifications

• A61K47/34

  Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) · CPC title

• A61K47/10

  Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers · CPC title

• A61L2300/41

  Anti-inflammatory agents, e.g. NSAIDs · CPC title

• A61L2300/404

  Biocides, antimicrobial agents, antiseptic agents · CPC title

• A61L2300/43

  Hormones, e.g. dexamethasone · CPC title